Finerenone

Which Drugs Prevent Heart Failure?

by Prateek Chopra | May 21, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure (HF) prevention has evolved from traditional risk-factor management to targeted pharmacologic intervention across the HF continuum. Contemporary evidence supports multiple cardiometabolic therapies that prevent incident HF, delay progression from pre-HF to symptomatic disease, and reduce HF hospitalization (HFH). The findings were presented at Heart Failure 2026, […]

Which Drugs Prevent Heart Failure? Read Post »

Leave a Comment / ESC-HF Day 2 / bluetree.healthcare@gmail.com / July 30, 2026 / Cardiometabolic Disease Prevention, Finerenone, GLP-1 Receptor Agonists, Heart Failure Prevention, SGLT2 Inhibitors

Differential Use of Diuretics in Hypertensive Patients with Chronic Kidney Disease (CKD): The Joint ESH–ERA Session

by Prateek Chopra | June 18, 2026 | Cardiology Conferences | ESH 2026 Clinical Background: Hypertension in chronic kidney disease (CKD) arises from sodium retention, RAAS activation, sympathetic overactivity, and endothelial dysfunction. High dietary salt intake accelerates CKD progression via proteinuria and glomerular hyperfiltration, making diuretics central to hypertension management. Evidence & Guideline Recommendations: Treatment-Resistant Hypertension: Clinical Implications: A tailored, CKD

Differential Use of Diuretics in Hypertensive Patients with Chronic Kidney Disease (CKD): The Joint ESH–ERA Session Read Post »

Leave a Comment / ESH Day 4 / bluetree.healthcare@gmail.com / July 29, 2026 / Chronic Kidney Disease (CKD), Diuretic Therapy, Finerenone, Hypertension Management, SGLT2 Inhibitors

Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism?

by Prateek Chopra | June 4, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Non-steroidal mineralocorticoid receptor antagonists (MRAs) and aldosterone synthase inhibitors (ASIs) are emerging therapeutic approaches in primary aldosteronism (PA). Evidence from randomized trials, single-arm studies, real-world analyses, and ongoing clinical programs evaluates the efficacy, biochemical outcomes, and safety of finerenone, baxdrostat, and dexfadrostat. Key Evidence – MRAs:

Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism? Read Post »

Leave a Comment / ESH Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Aldosterone Synthase Inhibitors (ASI), Finerenone, Non-Steroidal Mineralocorticoid Receptor Antagonists (MRAs), Primary Aldosteronism, Resistant Hypertension

New Therapies in the Prevention of Cardiac Damage in Patientswith CKM Syndrome

by Prateek Chopra | June 3, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Cardiovascular-kidney-metabolic (CKM) syndrome encompasses overlapping progression of cardiovascular disease, chronic kidney disease, obesity, diabetes, and hypertension, resulting in persistent myocardial injury and increased heart failure risk. Contemporary management focuses on integrated therapies targeting cardio-renal-metabolic pathways to prevent progressive cardiac damage. Key Pathophysiology & Mechanisms: Emerging Therapeutic

New Therapies in the Prevention of Cardiac Damage in Patientswith CKM Syndrome Read Post »

Leave a Comment / ESH Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiorenal Protection, Cardiovascular-Kidney-Metabolic (CKM) Syndrome, Finerenone, Semaglutide, SGLT2 Inhibitors

Inflammation, Body Mass Index, and Cardiovascular Outcomes in Chronic Kidney Disease and Type 2 Diabetes

by Prateek Chopra | July 3, 2026 | Diabetes Conferences | ADA 2026 Cardiovascular Risk Assessment Methods Study Population Key Findings Effect of Finerenone Clinical Implications Low-grade inflammation and obesity jointly contribute to cardiovascular risk in CKD and T2D. Finerenone maintained consistent cardioprotective benefits across all hsCRP and BMI categories, supporting its use for cardiovascular risk reduction in this high-risk

Inflammation, Body Mass Index, and Cardiovascular Outcomes in Chronic Kidney Disease and Type 2 Diabetes Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiovascular Risk, Chronic Kidney Disease (CKD), Finerenone, Inflammation (hsCRP), Type 2 Diabetes (T2DM)

Comparative Efficacy of Combined Finerenone and Conventional-Dose ARB vs. High-Dose ARB on Renal Markers in Type 2 Diabetes Patients with Stage 1–3 Diabetic Nephropathy Receiving SGLT2i

by Prateek Chopra | July 1, 2026 | Diabetes Conferences | ADA 2026 Study Overview Methods Treatment Groups Baseline Characteristics Renal Outcomes Cardiometabolic Outcomes Safety Findings Clinical Implications High-dose ARB therapy and conventional-dose ARB combined with finerenone demonstrated similar improvements in renal markers over 6 months in patients with diabetic nephropathy receiving SGLT2 inhibitors. Both strategies appear to be viable

Comparative Efficacy of Combined Finerenone and Conventional-Dose ARB vs. High-Dose ARB on Renal Markers in Type 2 Diabetes Patients with Stage 1–3 Diabetic Nephropathy Receiving SGLT2i Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / ADA 2026, Chronic Kidney Disease (CKD), Diabetic Nephropathy, Finerenone, SGLT2 Inhibitors, Type 2 Diabetes (T2DM)